Scientific article

A new era of antiretroviral drug toxicity

Published inAntiviral therapy, vol. 14, no. 2, p. 165-179
Publication date2009

The spectrum of drugs used in HIV-infected patients has dramatically changed since triple antiretroviral combinations were introduced, albeit at the expense of some severe adverse events, in 1996. Abandonment of stavudine in countries that can afford it, new drugs from new classes with a wide therapeutic window and the impressive scale-up of drug access in resource-limited settings are several of the key new events. Drug safety is likely to be the most important factor to distinguish one antiretroviral regimen from another. We review life-threatening adverse events, adverse events of new investigational or recently marketed drugs, adverse events with a genetic component and tissue-specific adverse events of fat, heart, bone, kidney and liver.

  • Anti-Retroviral Agents/ adverse effects
  • Bone Diseases, Metabolic/chemically induced
  • Cardiovascular Diseases/chemically induced
  • Drug Evaluation
  • Drug-Induced Liver Injury
  • Genetic Variation
  • HIV/drug effects
  • HIV Infections/ drug therapy/genetics
  • HIV-Associated Lipodystrophy Syndrome/chemically induced
  • Health Resources
  • Humans
  • Kidney Diseases/chemically induced
Research group
Citation (ISO format)
CALMY, Alexandra et al. A new era of antiretroviral drug toxicity. In: Antiviral therapy, 2009, vol. 14, n° 2, p. 165–179.
ISSN of the journal1359-6535

Technical informations

Creation07/12/2010 2:36:42 PM
First validation07/12/2010 2:36:42 PM
Update time03/14/2023 3:54:14 PM
Status update03/14/2023 3:54:14 PM
Last indexation05/02/2024 11:41:00 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack